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Abstract
Background Gastric cancer is responsible for 10 % of all
cancer-related deaths worldwide. With improved operative
techniques and neo-adjuvant therapy, survival rates are increas-
ing. Outcomes of interest are shifting to quality of life (QOL),
withmany different tools available. The aim of this study was to
assess which patient-reported outcome measures (PROMs) are
used to measure QOL after a gastrectomy for cancer.
Methods A comprehensive search was conducted for
original articles investigating QOL after gastrectomy. Two
authors independently selected relevant articles, conducted
clinical appraisal and extracted data (P.J. and J.S.).
Results Out of 3414 articles, 26 studies were included,
including a total of 4690 patients. These studies included
ten different PROMs, which could be divided into generic,
symptom-specific and disease-specific questionnaires. The
EORTC and the FACT questionnaires use an oncological
overall QOL module and an organ-specific module. Only
one validation study regarding the use of the EORTC after
surgery for gastric cancer was available, demonstrating
good psychometric properties and clinical validity.
Conclusions A great variety of PROMs are being used in
the measurement of QOL after surgery for gastric cancer. A
questionnaire with a general module along with a disease-
specific module for the assessment of QOL seems most
desirable, such as the EORTC and the FACT with their
specific modules. Both are developed in different treatment
modalities, such as in surgical patients. EORTC is the most
widely used questionnaire and therefore allows for compar-
ison of new studies to existing data. Future studies are needed
to assess content validity in surgical gastric cancer patients.
Keywords Quality of life  Gastric cancer  Gastrectomy 
PROMs
Gastric cancer is responsible for 10 % of all cancer-related
deaths worldwide, with the highest incidences in Eastern
Asia, Eastern Europe and South America [1]. Although
multiple treatment modalities exist, surgical resection of
the primary tumour and regional lymph nodes is still the
only curative treatment available for gastric cancer [2].
Currently, the 5-year survival rate after oesophageal
resection is approximately 20 % [3]. With the implemen-
tation of minimally invasive techniques and additional
treatments such as neo-adjuvant chemotherapy, survival
rates have improved and an according number of long-term
survivors exists [4–6]. Laparoscopic techniques have been
shown to improve quality of life sooner after surgery [7].
With increasing survival and decreased morbidity, a shift
in interest of outcome parameters is seen from survival and
morbidity rates to the impact of radical gastrectomy and
chemoradiotherapy on patient-reported outcomes, such as
quality of life (QOL) [8]. Information about QOL outcomes
should be an important outcome parameter in research
regarding the optimal treatment for gastric cancer.
The World Health Organization (WHO) defined QOL as
an individuals’ perception of their position in life in the
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cultural context and in the value system in which they live
and in relation to their goals, expectations, standards and
concerns [9]. QOL data provide direct measures of benefit
as perceived by the patient and may be useful in clarifying
treatment preferences. Many different questionnaires are
available, both validated and non-validated, to assess the
quality of life [7]. Although the different instruments focus
on different aspects of QOL, no consensus exists as to
which instrument is optimal in the assessment of QOL after
gastrectomy for gastric cancer [10]. The aim of this sys-
tematic review was to assess which PROMs are used in the
assessment of QOL after surgery for gastric cancer.
Materials and methods
Literature search
To identify all relevant publications, a systematic search in
the bibliographic databases PubMed, EMBASE and The
Cochrane Library (via Wiley) from inception to 14 October
2014 was performed. Search terms included controlled
terms from MeSH in PubMed, Emtree in EMBASE.com as
well as free text terms. Free text terms were only used in
The Cochrane library. Search terms expressing ‘‘stomach
neoplasm’’ were used in combination with search terms
comprising ‘‘surgery’’. Moreover, an extensive search filter
for finding patient-reported outcome measures was used,
developed by the University of Oxford (‘‘Appendix’’). The
reference list of included articles was hand-searched for
relevant publications.
Selection criteria and definitions
Two authors (P.J. and J.S.) independently evaluated the
search findings for potential eligibility for systematic review
using the MEDLINE, EMBASE and Cochrane databases.
The inclusion criteria were: (1) article published in English
language; (2) only full-text articles, no abstracts or case
reports were included and (3) the study had to investigate
Fig. 1 Flow chart for the
selection of articles for
systematic review
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QOL after gastric resection using questionnaires (i.e. non-
structured interviews were not included). (4) Only patients
with gastric carcinomawere included. Studies that described
gastrointestinal stromal tumours (GIST) and benign tumours
were excluded. Distal, proximal, subtotal and total gastrec-
tomies were included.Wedge resections and local resections
were excluded. Regarding surgical techniques, both open
and minimally invasive procedures were included, and var-
ious reconstructive methods were included (i.e. Roux-en Y
or Billroth reconstruction).
Data extraction and quality assessment
The reviewers (P.J. and J.S.) extracted the following data
from each study: first author, title of the article, year of pub-
lication, type of study, type of gastrectomy, type of recon-
struction, number of patients included and thePROMsused to
assess QOL. All articles that were deemed suitable after full-
text analysiswere assessed for quality of the performed study.
Results
Study selection
Initially, the literature search of MEDLINE, EMBASE and
Cochrane resulted in 4529 hits, after removal of duplicates
3414 hits remained. The articles were screened based on
title and abstract by two different authors (P.J. and J.S.)
independently, and this resulted in a selection of 141 arti-
cles for full-text analysis. Of these 141 articles, another 115
were excluded since they did not meet the predefined cri-
teria as described in the methods section; 28 articles were
published in another language than English; 45 references
consisted only of conference abstracts; 39 articles included
a different subject; a final three articles were excluded
because they did not use questionnaires but self-reported
interviews for QOL assessment. Twenty-six articles
remained for further analysis. A flow chart of the article
selection is depicted in Fig. 1.
Table 1 Description of prospective cohort studies
Study Country Study type Patient (n) Aim QOL instruments Follow-up






Wu et al. [12] Taiwan Prospective, RCT 214 D1 versus D3
lymphadenectomy
Spitzer index Baseline, 6, 12,
24, 36, 48 and
60 months
Avery et al. [32] UK Prospective 58 QOL in patients that died






and 12, 18 and
24 months







24, 36, 48 and
60 months





Baseline, 3, 6, 9,
12, 18 months



















(range 3 - 34)
Kono et al. [18] Japan Prospective, RCT 47 Roux-en Y versus pouch
reconstruction
GSRS 3, 12, 48 months
Horvath et al. [16] Hungary Prospective, RCT 46 Roux-en Y versus pouch
reconstruction
GIQLI 6, 12 and
24 months
Scurtu et al. [25] Romania Prospective 39 Total gastrectomy with E–E
versus E–S anastomosis
Korenaga score 3 and 12 months






Baseline, 1, 3, 6
and 12 months
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Study characteristics
Twenty-six articles were included for full-text analysis, of
which twelve articles were prospective cohort studies, six
of which were randomized controlled trials, and fourteen
were retrospective cohort studies with prospective QOL
assessment, including a total of 4690 patients. One study
was a development and validation study [11]. There was
great dispersion in follow-up data, ranging from 6 months
to 5 years. An overview of the included articles is given in
Table 1 for prospective articles and Table 2 for retro-
spective studies.
The quality-of-life instruments
Twenty-six full-text articles were assessed regarding QOL
following surgical procedures for gastric cancer. In these
articles, a total of ten different PROMs were described. Dif-
ferent instruments focussed on different dimensions of the
QOL (i.e. physical, functional, social and emotional function).
The PROMs could be divided into separate categories,
as given in Table 3. First four generic instruments were
used, i.e. the Short Form-12 (SF-12), Sickness Impact
Profile (SIP), Spitzer index and EuroQol-5D (EQ-5D).
These instruments were used to compare results across
Table 2 Description of retrospective cohort studies
Study Country Study type Patient (n) Aim QOL instruments Follow-up














81 ± 80.7 months





Baseline, 3, 6, 9, 12,
18 and 24 months




EORTC QLQ-C30 49 months (range
41–89)
Buhl et al. [40] Germany Retrospective 104 Distal versus total
gastrectomy with
Roux-en Y or pouch
Spitzer index 12 months
Bae et al. [41] Korea Retrospective 391 Total versus subtotal EORTC QLQ-C30
EORTC QLQ-
STO22
27.5 ± 3.3 months














6 months to 5 year
range





Median 9 (6–19) years
Nakamura et al. [11] Japan Retrospective 883 Development and
validation of DAUGS
DAUGS20 3 and 6 months, 1, 2
and 3 years
Nakamura et al. [45] Japan Retrospective 165 Evaluate DAUGS in
patients after gastric
resection
DAUGS32 3–6 months, 6–1 year,
1–2 years, 1–3 years





Baseline, 3, 6, 9 and
12 months
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Table 3 Description of patient-reported outcome measures (PROMs)
Questionnaires Target population Dimensions
(number of
items)






Generic SIP [49] Very broad, tested in non-,
in- and out-patient with
different illnesses and
different severities




Recreation and pastimes (8)
Ambulation (10)
Mobility (10)





































small intestine, colon, and
rectum. And developed in
patients who underwent a
laparoscopic chole-
cystectomy






GSRS [15, 53] Developed for irritable
bowel syndrome and
peptic ulcer disease. Later
validated in upper
gastrointestinal patient
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Table 3 continued
Questionnaires Target population Dimensions
(number of
items)






Cancer specific EORTC QLQ-C30
[22]
Cancer patients (developed
in lung cancer patients)













Nausea and vomiting (2)
Single items (6)
FACT-G [19] General cancer, developed
in breast, lung and
colorectal cancer









































Single items (14) Easy (0–2 per
question) (0–28)
1
DAUGS20 [11] Developed to assess
postoperative dysfunction
after surgery for gastric
and oesophageal
carcinoma
Single items (20) Easy (1–5 per
question) (34–170)
2







Difficulty in stool formation and
passage
SIP Sickness Impact Profile, SF-12 The 12-item Short Form Healthy Survey, EQ-5D EuroQoL-5D, GIQLI Gastrointestinal Quality of Life Index,
GSRS Gastrointestinal Symptom Rating Scale, EORTC QLQ European Organization for Research and Treatment QOL Questionnaire, FACT-G
Functional Assessment of Cancer Therapy—General, DAUGS Dysfunction After Upper Gastrointestinal Surgery, FACT-Ga Functional
Assessment of Cancer Therapy for patients with Gastric Cancer
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different conditions of health. These questionnaires are
developed and validated to measure QOL in a general
population. The Spitzer index is a global health assessment
tool, which assess activity, daily living, health, support
system and outlook. No symptom- or treatment-specific
questions are included in this questionnaire [12, 13]. The
SF-12, SIP and EQ-5D have all been used once, and three
out of the twenty studies have used the Spitzer index.
Secondly, symptom-specific questionnaires were used,
namely the Gastrontestinal Quality of Life Index (GIQLI)
and theGastrointestinal SymptomRating Scale (GSRS). The
GIQLI is developed in patients with benign and malignant
disorders [14]. The GRSRwas initially developed in patients
with irritable bowel disease and not specifically designed for
oncological or postoperative patients [15]. Only one study
assessed QOL with the GIQLI score [16]. The GSRS score
was used in two studies and allowed for overall assessment
and of assessment of the individual items [17, 18]. GIQLI
and GSRS are specifically designed for gastrointestinal
symptoms, not for overall QOL.
A third group consists of disease-specific questionnaires.
The Functional Assessment of Cancer Therapy (FACT)
questionnaires consist of a general health module (FACT-
G), and disease-specific modules can be added, such as
FACT-Ga for gastric cancer [19, 20], thus allowing for the
assessment of overall QOL and assessment of disease-
specific symptoms by adding the appropriate module. The
FACT-Ga is developed in patients with gastric cancer who
underwent different treatment modalities, such as gastrec-
tomy, chemotherapy and radiotherapy [20]. One study has
used the FACT questionnaire [21].
The European Organisation for Research and Treatment
of Cancer (EORTC) questionnaires work in a similar
fashion, consisting of a general health questionnaire, the
EORTC QLQ-C30, which is aimed specifically at cancer
patients [22]. Disease-specific modules can be added, such
as the EORTC QLQ-STO22 for gastric cancer. The
EORTC QLQ-STO22 is developed in patients with gastric
cancer who underwent different treatment modalities, such
as surgery, chemo- or chemoradiotherapy in curative or
palliative setting [23, 24]. The EORTC QLQ-STO22 and
the FACT-Ga are site-specific questionnaires that are
related to gastric cancer [20, 23]. Fifteen out of twenty-six
studies have used the EORTC QLQ-C30 of which twelve
studies also included the EORTC QLQ-STO22 module.
Only one validation study was identified, which assessed
the use of the STO22module in patients who were operated in
curative or palliative setting. The module was found to have a
good internal consistency (Crohnbach’s alpha’s[0.7) andwas
deemed reliable and sensitive to changes in both individual
patient status and differences between patient groups [23].
Postoperative patients are considered a different entity in
the DAUGS20 and Korenaga’s score, and these
questionnaires focus specifically on patients following gas-
trectomy for cancer [11]. The questionnaires measure treat-
ment-specific symptoms, such as appetite, swallowing,
heartburn and diarrhoea [25, 26]. The Dysfunction After
Upper Gastrointestinal Surgery (DAUGS20) questionnaire
was originally designed in gastric and oesophageal cancer
patientswho had undergone surgery. TheDAUGS is designed
to measure QOL postoperative, and no baseline measurement
is included [26]. An overview of the different PROMs is
provided in Table 3.
Discussion
The here-presented systematic review aimed to review
what PROMs are available in assessing the QOL in patients
with gastric cancer who undergo gastric resection. Ten
PROMs were identified in 26 studies regarding different
surgical techniques or comparison of different treatment
modalities.
Gastrectomy with radical resection margins of 5 cm
around the tumour along with adequate lymfadenectomy is
currently the only curative therapy available in gastric cancer
[27]. Overall QOL and even separate domains of QOL may
differ between different treatment modalities. Question
remains whether surgical patients should be considered a
separate entity, and whether questionnaires should be
developed or adapted for patients undergoing gastrectomy. In
an optimal setting, the PROMs should allow for overall
assessment of QOL, along with specific modules to assess
specific effects associatedwith the disease and treatment [28].
The DAUGS20 and Korenaga’s score consider surgical
patients to be a different entity. These questionnaires are
specifically aimed at the postoperative patient who had sur-
gery for gastric cancer [25, 29]. No validation studies
regarding these questionnaires were available. DAUGS20
and Korenaga’s score are not developed for overall QOL
assessment and are preferably to be used alongside a general
QOL PROM [26, 30]. Since the questionnaires aim specifi-
cally at the postoperative patient, they do not allow for
comparison of QOL among different treatment modalities
such as chemotherapy and radiotherapy. They do allow for
comparison of QOL among different surgical techniques.
The EORTC and FACT questionnaires consider gastric
cancer patients as a whole. Both the EORTC and FACT
questionnaires consist of a general cancer QOL module to
which organ-specific module can be added (EORTC QLQ-
STO22 and FACT-Ga), allowing for general and disease-
specific QOL assessment between different treatment
modalities. Both questionnaires were developed in patients
with gastric cancer undergoing different treatment modal-
ities, including surgery. With regard to comparability and
reproducibility, the EORTC was used more often and
1926 Surg Endosc (2016) 30:1920–1929
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might therefore allow for comparison to conducted studies,
taking into account the heterogeneity in research questions,
time points of QOL measurement and follow-up.
Fourteen (54 %) of the included studies consisted of
retrospective cohort studies. Only six randomized studies
were available. Differences in study design, endpoints,
patient groups, surgical techniques and time points in the
studies further limited assessment and pooling of data. No
validation studies were available for the use of these
PROMs in patients undergoing surgery for gastric cancer;
hence, comparison of the performance of the different
PROMs with regard to validity, internal consistency and
discriminative ability was not possible.
Future research should focus on content validity of the
used questionnaires in postgastrectomy patients in order to
assess whether all the important domains are truly assessed
and no items are missing. In order to further assess the use
of PROMs in treatment of individual patients, our project
group is currently aiming to develop a core outcome set of
patient-reported outcomes in gastric cancer patients.
In conclusion, in the assessment of QOL in surgical gastric
cancer patients, a great variety of PROMs are being used. A
questionnaire with a general module to assess overall QOL,
which can be supplemented with disease-specific modules
allowing for the assessment or QOL of different treatment
modalities, seems to bemost desirable.With regard to current
practice, the EORTC QLQ-C30 with STO22 module was
developed in gastric cancer patientswith different treatments,
and it is used most widely, allowing for comparison of new
data to studies that were already conducted. Future research
should assess the need for treatment-specific modules.
Compliance with ethical standards
Disclosures The authors, Jennifer Straatman, Nicole van der Wie-
len, Pieter J. Joosten, Caroline B. Terwee, Miguel A. Cuesta, Elise P.
Jansma and Donald L. van der Peet, declare that they have no conflict
of interest
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
Appendix
Search PubMed Query 17 November 2014 Items
found
#9 1610
Search PubMed Query 17 November 2014 Items
found
Search #8 NOT (‘‘addresses’’[Publication Type]










‘‘news’’[Publication Type] OR ‘‘newspaper
article’’[Publication Type] OR ‘‘patient
education handout’’[Publication Type] OR
‘‘popular works’’[Publication Type] OR
‘‘congresses’’[Publication Type] OR
‘‘consensus development
conference’’[Publication Type] OR ‘‘consensus
development conference, nih’’[Publication
Type] OR ‘‘practice guideline’’[Publication
Type]) NOT (animals[mh] NOT humans[mh])
#8 Search #5 AND #6 AND #7 1625
#7 Search (HR-PRO[tiab] OR HRPRO[tiab] OR
HRQL[tiab] OR HRQoL[tiab] OR QL[tiab] OR
QoL[tiab] OR quality of life[tiab] OR life
quality[tiab] OR health index*[tiab] OR health
indices[tiab] OR health profile*[tiab] OR
health status[tw] OR ((patient[tiab] OR
self[tiab] OR child[tiab] OR parent[tiab] OR
carer[tiab] OR proxy[tiab]) AND ((report[tiab]
OR reported[tiab] OR reporting[tiab]) OR
(rated[tiab] OR rating[tiab] OR ratings[tiab])
OR based[tiab] OR (assessed[tiab] OR
assessment[tiab] OR assessments[tiab]))) OR
((disability[tiab] OR function[tiab] OR
functional[tiab] OR functions[tiab] OR
subjective[tiab] OR utility[tiab] OR
utilities[tiab] OR wellbeing[tiab] OR well
being[tiab]) AND (outcome[tiab] OR
outcomes[tiab] OR index[tiab] OR indices[tiab]
OR instrument[tiab] OR instruments[tiab] OR
measure[tiab] OR measures[tiab] OR
questionnaire[tiab] OR questionnaires[tiab] OR
profile[tiab] OR profiles[tiab] OR scale[tiab]
OR scales[tiab] OR score[tiab] OR scores[tiab]
OR status[tiab] OR survey[tiab] OR
surveys[tiab])))
1657339
#6 Search ‘‘gastrectomy’’[MeSH] OR
((gastrectom*[tiab] OR ‘‘gastric
resection’’[tiab] OR gastrectom*[ot] OR
‘‘gastric resection’’[ot]) NOT medline[sb])
27902
#5 Search ‘‘Stomach Neoplasms’’[Mesh] OR
Stomach Neoplasm*[tiab] OR Gastric
Neoplasm*[tiab] OR Stomach Cancer*[tiab]
OR Gastric Cancer*[tiab] OR Stomach
carcinoma*[tiab] OR gastric carcinoma*[tiab]
OR stomach tumor*[tiab] OR stomach
tumour*[tiab] OR gastric tumor*[tiab] OR
gastric tumour*[tiab] OR stomach
neoplasia*[tiab] OR cardia carcinoma*[tiab]
OR linitis plastica[tiab] OR Stomach
87062
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Search PubMed Query 17 November 2014 Items
found
Neoplasm*[ot] OR Gastric Neoplasm*[ot] OR
Stomach Cancer*[ot] OR Gastric Cancer*[ot]
OR Stomach carcinoma*[ot] OR gastric
carcinoma*[ot] OR stomach tumor*[ot] OR
stomach tumour*[ot] OR gastric tumor*[ot] OR
gastric tumour*[ot] OR stomach neoplasia*[ot]
OR cardia carcinoma*[ot] OR linitis
plastica[ot]
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